Sandoz Gains Biosimilar Edge, Boosts Cancer Treatment Portfolio
Update: 2025-11-12
Description
Sandoz secures biosimilar rights to Perjeta, boosting its cancer treatment portfolio and potentially outpacing Roches revenue projections. This strategic move addresses investor concerns and positions Sandoz for growth in the biosimilar market.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
